Skip to main content

16-08-2018 | Non-small cell lung cancer | Article

Management of EGFR mutation-positive NSCLC: Two steps forward, looking back

Caroline E McCoach , Howard L West
Despite initial progress with tyrosine kinase inhibitors (TKIs) for treating EGFR-mutated non-small-cell lung cancer (NSCLC), treatment resistance has become a significant obstacle. Dr Caroline McCoach (Helen Diller Family Comprehensive Cancer Center, CA, USA) and Dr Howard (Jack) West (Swedish Cancer Institute, WA, USA) survey insights gained into tumor biology and resistance mechanisms, as well as lessons learned from clinical trials, which may illuminate the way forward for treatment of EGFR-mutated NSCLC.

Please log in to get access to this content

Related topics

More on this topic

image credits